January 29-31, 2019 | San Francisco
 

Day One
Wednesday 30th January, 2019

Day Two
Thursday 31st January, 2019

08.05
Chair’s Opening Remarks

Enhancing Preclinical Development & Translation Research

08.15
Biomarkers for Basic and Translational Research

  • Ronald Kohanski Deputy Director, Division of Aging Biology, National Institute on Aging, NIH

Synopsis

  • Pillars of aging are interactive, so we might expect complexity in any biomarkers of aging
  • Linking biomarkers to physiological declines that could be measured through increased frailty or decreased activities of daily living
  • Exploring the need to accommodate variance in biomarkers and account for “medical conditions that are not age” as potential exclusion criteria for the occurrence of outliers with increasing age

08.45
Altered Methylation Landscapes in Biological Aging

  • Morgan Levine Assistant Professor, Department of Pathology, Yale School of Medicine

Synopsis

  • Discussing differences between existing epigenetic measures of aging, e.g. Epigenetic Clocks
  • Presenting novel higher-order epigenetic measures
  • Highlighting the application of such measures for evaluating Geroprotective Interventions

09.15
Rejuvenation Biotechnology: Addressing Delivery Challenges in Gene & Stem Cell Therapy

  • Aubrey de Grey CSO, SENS Foundation & VP of New Technology Discovery, AgeX Therapeutics

Synopsis

  • Analyzing how regenerative medicine and other new biomedical technologies will eventually be so comprehensive that people will stay truly youthful however long they live
  • Outlining an innovative approach for stem cell delivery for neurodegenerative diseases
  • Exploring gene therapy potential in aging and how to deliver large cargos with very high insertion-site specificity

09.45
Morning Refreshments & Networking

10.15
Therapies for Thymic Regeneration and Cholesterol Catabolism

  • Reason Co-Founder & CEO, Repair Biotechnologies

Synopsis

  • Developing a safe and effective therapy for thymic regeneration and immune system restoration
  • Building on LysoSENS to develop a gene therapy for cholesterol catabolism
  • Presenting the latest data

10.45
Hard Problems Need Hard Assets: Building, Discovering & Translating A Small Molecule Senolytic

Synopsis

  • Developing first-in-class small molecule senolytic drugs for pathways of aging
  • Analyzing the latest data

11.15
Panel Discussion: Tackling Preclinical & Translational Challenges in Aging-Related Therapeutics

Synopsis

  • How applicable to human aging is any given result in a model organism?
  • How to promote advances in biomarker discovery and validation in aging
  • Defining routes for translational success from discovery to clinic – what will be the key factors for generating successful results?
  • Standardizing different classes of therapeutic approaches to achieve effective anti-aging outcomes

12.00
Lunch & Networking

Exploring Clinical Development, Regulatory & Commercial Considerations

13.00
TAMEing Aging

  • Nir Barzilai Professor & Director, Institute for Aging Research, Albert Einstein College of Medicine

Synopsis

  • Exploring metformin – a generic, cheap and safe drug used to treat Type 2 diabetes mellitus (T2DM), which targets biology of aging, extends health span and life span in animals
  • Showing that metformin targets this biology in muscle and adipose tissue of elderly
  • Numerous clinical and observational studies in humans show that metformin therapy delays diabetes, cardiovascular diseases, all kind of cancers, Alzheimer’s and mortality
  • Describing a novel study design that addresses the need to define aging in a clinical way
  • Addressing regulation – FDA is helping design this study so if outcomes are achieved aging will become a regulatory target

13.30
Innovating R&D for Ageing: A Systematic, Comprehensive & Innovative Approach to The Development of Therapies for Ageing

  • Sree Kant Head of Business Development, Life Biosciences

Synopsis

  • Analyzing the fragmentated clinical translation of pathways that control biological ageing
  • Discussing current business/investment models in R&D and the their short comings as
    applicable to ageing research
  • Developing an innovative drug development engine for ageing – establishing Life
    Biosciences
  • Discussing the Life Bioscience’s investment and operating model, the science underlying
    the programs, and how we can translate drugs to treat ageing into the clinic

14.00
Mastermind Session: Supporting the Successful Discovery & Development of Innovative Medicines Against Diseases of Aging

Synopsis

This session facilitates in-depth discussions among participants in an informal environment. After splitting into groups, participants will discuss key issues and challenges regarding the current landscape of aging research and related drug development.

14.45
Afternoon Refreshments & Networking

15.15
TORC1 Inhibition as an Immunotherapy to Decrease Respiratory Tract Infections in the Elderly

Synopsis

  • Discussing the role of mTOR in aging
  • Overviewing resTORbio’s TORC1 inhibitors
  • Reviewing of Phase 2 clinical trials analyzing the effects of TORC1 inhibitors on immune function and respiratory tract infection rates in elderly subjects

15.45
Addressing The Challenges of the Aging Population Requires Taking A Holistic View

Synopsis

  • Analyzing the link between general function and clinical outcomes in the elderly
  • What can we learn from rare genetic disorders?
  • How to address variability in target populations?
  • Addressing the need for innovation in clinical trial design in genetic and age-related disorders

16.15
Clinical Evaluation & Regulatory Considerations in the Approval of Biopharmaceuticals for Health-Span Indications

  • Brian Huber Chief Operations & Scientific Officer, Carolina Longevity Institute LLC (CLI)

Synopsis

  • Discussing how the clinical development strategy and regulatory approval pathway for health-span and longevity related biopharmaceutical drugs is still evolving and being established
  • Exploring lessons learned from other examples where the clinical indication needed to be established and the approval pathway created
  • Drawing parallels and hypothesizing pathways

16.45
Chair’s Closing Remarks